Chong Charing C N, Lee Kit F, Cheung Sunny Y S, Chu Clement C M, Fong Anthony K W, Wong John, Hui Joyce W Y, Fung Andrew K Y, Lok Hon T, Lo Eugene Y J, Chan Stephen L, Yu Simon C H, Ng Kelvin K C, Lai Paul B S
Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Prince of Wales Hospital, the Chinese University of Hong Kong, Shatin, Hong Kong.
Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Prince of Wales Hospital, the Chinese University of Hong Kong, Shatin, Hong Kong.
HPB (Oxford). 2020 Aug;22(8):1121-1127. doi: 10.1016/j.hpb.2020.01.008. Epub 2020 Feb 8.
Microwave (MWA) and radiofrequency ablation are the commonly used local ablation for hepatocellular carcinoma (HCC). Studies comparing both techniques are scarce. The aim of this study was to compare the efficacy of MWA versus RFA as a treatment for HCC.
Patients with HCC who were suitable for local ablation were randomized into MWA or RFA. All patients were followed up regularly with contrast-enhanced computed tomography (CT) performed at 1, 3, 6 and 12 months after ablation. Both patients and the radiologists who interpreted the post-procedure CT scans were blinded to the treatment allocation. Treatment-related morbidity, overall and disease-free survivals were analyzed.
A total of 93 patients were recruited. Among them, 47 and 46 patients were randomized to MWA and RFA respectively. Patients in two groups were comparable in baseline demographics and tumor characteristics. With a median follow-up of around 30 months, there were no significant difference in the treatment-related morbidity, overall and disease-free survivals. MWA had a significantly shorter overall ablation time when compared with RFA (12 min vs 24 min, p < 0.001).
MWA is no different to RFA with respect to completeness of ablation and survivals. It is, however, as safe and effective as RFA in treating small HCC.
微波消融（MWA）和射频消融是肝细胞癌（HCC）常用的局部消融方法。比较这两种技术的研究较少。本研究旨在比较MWA与RFA治疗HCC的疗效。
将适合局部消融的HCC患者随机分为MWA组或RFA组。所有患者在消融后1、3、6和12个月定期进行对比增强计算机断层扫描（CT）随访。患者和解读术后CT扫描结果的放射科医生均对治疗分配情况不知情。分析治疗相关的发病率、总生存率和无病生存率。
共招募了93例患者。其中，47例和46例患者分别被随机分配至MWA组和RFA组。两组患者在基线人口统计学和肿瘤特征方面具有可比性。中位随访时间约为30个月，治疗相关的发病率、总生存率和无病生存率无显著差异。与RFA相比，MWA的总消融时间明显更短（12分钟对24分钟，p < 0.001）。
MWA在消融完整性和生存率方面与RFA无异。然而，在治疗小肝癌方面，它与RFA一样安全有效。
